TRPV1 antagonist 3,99.30%

产品编号:Bellancom-144372| 分子式:C23H25N3OS| 分子量:391.53

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
Bellancom-144372
3200.00 杭州 北京(现货)
Bellancom-144372
5200.00 杭州 北京(现货)
Bellancom-144372
10300.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

TRPV1 antagonist 3

产品介绍 TRPV1 antagonist 3 (Compound 7q) 是一种有效的 TRPV1 拮抗剂,对 capsaicin 的 IC50 值为 2.66 nM。 TRPV1 antagonist 3 具有模式选择性和良好的口服生物利用度 (F = 60%),可透过血脑屏障。
生物活性

TRPV1 antagonist 3 (Compound 7q) is a potent TRPV1 antagonist with an IC50 of 2.66 nM against capsaicin. TRPV1 antagonist 3 is mode-selective, oral bioavailable (F = 60%) and CNS-penetrant.

体外研究

TRPV1 antagonist 3 (Compound 7q) is highly selective for the TRPV1 receptor relative to other TRP channels.
TRPV1 antagonist 3 shows acceptable aqueous solubility (solubility at pH 7.4 = 26 μg/mL) .

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

TRPV1 antagonist 3 (Compound 7q) (0-30 mg/kg; i.p.; 30 min) shows anti-nociceptive effect mainly mediated by blocking CAP-activated channel.
TRPV1 antagonist 3 (0-100 mg/kg; i.g.) had no obvious thermal effect in rats.
TRPV1 antagonist 3 (10 mg/kg; i.v.) shows a good concentration in the brain at 0.5 h, with value of 2311 ng/g, and has good CNS penetration, with a brain/plasma ratio of 1.66.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: KM male mice (18-22 g), capsaicin, acetic acid, and thermal induced pain model
Dosage: 3, 10, and 30 mg/kg. 20 μL of solution of capsaicin (16 mg/20 mL) was injected s.c. under the skin of the dorsal surface of the right hind paw, or injected with 0.6% acetic acid (0.1 mL/10 g/mouse i.p.).
Administration: Intraperitoneally administration; 30 min
Result: In capsaicin-induced nociception, licking time decreased significantly in a dose-dependent manner. In acid-induced nociception, no significant anti-nociceptive activities were found compared with the control (SB-705498 and BCTC) at all dosage. In thermal-induced nociception, the latency time of nociceptive responses was increased at the doses of 10 and 30 mg/kg.
Animal Model: Spragur-Dawley male rats (220-250 g)
Dosage: 10 mg/kg or 20 mg/kg
Administration: Intravenous injection of 10 mg/kg or oral dose of 20 mg/kg (Pharmacokinetic Analysis)
Result: In vivo pharmacokinetic parameters of TRPV1 antagonist 3 in rats (n=3)
Parameters IV PO
t1/2 (h) 0.106 ± 0.076
t1/2, ka (h) 0.462 ± 0.096
t1/2, k10 (h) 0.527 ± 0.106
ka (1/h) 1.65 ± 0.364
k10 (1/h) 12.076 ± 2.337 1.133 ± 0.358
V (L/kg) 0.003 ± 0.001 0.016 ± 0.006
CL (L/h/kg) 0.024 ± 0.013 0.022 ± 0.01
Tmax (h) 0.711 ± 0.144
Cmax (ng/mL) 311.377 ± 108.017
AUC 0-inf (ng/mL*h) 495.955 ± 214.634 598.873 ± 212.319
MRT (h)
体内研究

TRPV1 antagonist 3 (Compound 7q) (0-30 mg/kg; i.p.; 30 min) shows anti-nociceptive effect mainly mediated by blocking CAP-activated channel.
TRPV1 antagonist 3 (0-100 mg/kg; i.g.) had no obvious thermal effect in rats.
TRPV1 antagonist 3 (10 mg/kg; i.v.) shows a good concentration in the brain at 0.5 h, with value of 2311 ng/g, and has good CNS penetration, with a brain/plasma ratio of 1.66.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: KM male mice (18-22 g), capsaicin, acetic acid, and thermal induced pain model
Dosage: 3, 10, and 30 mg/kg. 20 μL of solution of capsaicin (16 mg/20 mL) was injected s.c. under the skin of the dorsal surface of the right hind paw, or injected with 0.6% acetic acid (0.1 mL/10 g/mouse i.p.).
Administration: Intraperitoneally administration; 30 min
Result: In capsaicin-induced nociception, licking time decreased significantly in a dose-dependent manner. In acid-induced nociception, no significant anti-nociceptive activities were found compared with the control (SB-705498 and BCTC) at all dosage. In thermal-induced nociception, the latency time of nociceptive responses was increased at the doses of 10 and 30 mg/kg.
Animal Model: Spragur-Dawley male rats (220-250 g)
Dosage: 10 mg/kg or 20 mg/kg
Administration: Intravenous injection of 10 mg/kg or oral dose of 20 mg/kg (Pharmacokinetic Analysis)
Result: In vivo pharmacokinetic parameters of TRPV1 antagonist 3 in rats (n=3)
Parameters IV PO
t1/2 (h) 0.106 ± 0.076
t1/2, ka (h) 0.462 ± 0.096
t1/2, k10 (h) 0.527 ± 0.106
ka (1/h) 1.65 ± 0.364
k10 (1/h) 12.076 ± 2.337 1.133 ± 0.358
V (L/kg) 0.003 ± 0.001 0.016 ± 0.006
CL (L/h/kg) 0.024 ± 0.013 0.022 ± 0.01
Tmax (h) 0.711 ± 0.144
Cmax (ng/mL) 311.377 ± 108.017
AUC 0-inf (ng/mL*h) 495.955 ± 214.634 598.873 ± 212.319
MRT (h)
性状Solid
溶解性数据
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
参考文献

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


服务热线

13911702513
18601927057

微信客服